Can tremelimumab be used in combination?

Tremelimumab (tremelimumab) can be used in combination with other drugs. In clinical practice, temsitumumab is often used in combination with other immune checkpoint inhibitors, chemotherapy drugs or targeted therapy drugs. These combination treatment options are designed to act on tumor cells simultaneously through multiple pathways, thereby enhancing the therapeutic effect.

In the treatment of unresectable hepatocellular carcinoma (uHCC), temtumumab can be used in combination with drugs that block PD-L1 antibodies, such as durvalumab, to achieve better therapeutic effects. It can also be used in combination with platinum-based chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities. Texitumumab and durvalumab are immune checkpoint inhibitors with complementary mechanisms of action that can enhance the effect of T cells on tumor cells. Texitumumab is a monoclonal antibody that inhibits cytotoxic T lymphocyte antigen 4 (CTLA-4), while durvalumab is a monoclonal antibody that blocks the binding of PD-L1 to PD-1 and inhibits the PD-L1/PD-1 pathway, which can further activate the immune system's ability to attack tumors.xa0

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.